We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research compound — not a dietary supplement
Methylene Blue is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Methylene Blue studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 2014–2020 with a typical study size of 26 participants.
Based on 5 studies · 2 RCTs · 52 total participants
Confidence
LowBy outcome
Methylene Blue has an evidence score of 3/10 — emerging evidence based on 5 indexed studies. A century-old dye and approved drug for methemoglobinemia, used grey-market at low doses as a mitochondrial 'nootropic' and longevity aid. Small human brain-imaging trials suggest low doses can modestly aid memory/oxygen metabolism; longevity/skin evidence is preclinical. Narrow safe-dose window and real interactions (serotonin syndrome). Off-label/research use, not a supplement. Representative study: PMID 26961091.
The commonly studied dose of Methylene Blue is No validated longevity dose. Nootropic use is LOW-dose (research used roughly 0.5–4 mg/kg in studies; biohacker oral use is often ~10–25 mg), USP-grade only. Higher doses become pro-oxidant and risk toxicity. Off-label/research use, not an approved regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Notable regimens that report including Methylene Blue — documented, not endorsed.
Last reviewed June 2026 · evidence from 5 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Methylene blue (methylthioninium chloride)
A century-old dye and approved drug for methemoglobinemia, used grey-market at low doses as a mitochondrial 'nootropic' and longevity aid. Small human brain-imaging trials suggest low doses can modestly aid memory/oxygen metabolism; longevity/skin evidence is preclinical. Narrow safe-dose window and real interactions (serotonin syndrome). Off-label/research use, not a supplement.
Low-dose methylene blue has a genuine mitochondrial mechanism and small randomized human neuroimaging studies showing modest memory/brain-metabolism effects, but there are no human longevity outcomes, the dose-response is hormetic (higher doses harm), and it carries serious interactions (serotonin syndrome, G6PD hemolysis) — so the evidence is early and the safe window narrow.
Methylene blue (methylthioninium chloride) is a 150-year-old synthetic dye that is also an FDA-approved drug — used intravenously to treat methemoglobinemia and as a surgical stain.
In the biohacker/longevity world it is taken orally at low doses as a mitochondrial 'nootropic.' Its mechanism is genuinely interesting: at low concentrations it acts as an alternative electron carrier in the mitochondrial electron-transport chain, accepting electrons and donating them to cytochrome c / oxygen, which can increase cellular oxygen consumption and ATP production and provides antioxidant/redox-cycling effects.
Small randomized human neuroimaging studies (functional MRI) found low-dose methylene blue increased functional MRI responses and modestly improved memory-task performance and brain oxygen metabolism.
Preclinical work suggests neuroprotection in models of cerebral ischemia and anti-aging effects on skin fibroblasts (it has been explored as a cosmetic antioxidant).
The honest picture is that the human evidence is limited to small short-term cognitive/imaging studies — there are no human longevity outcomes — and methylene blue has important caveats: it has a hormetic (biphasic) dose-response, so higher doses become pro-oxidant and harmful; it is a potent monoamine-oxidase inhibitor, creating a serious risk of serotonin syndrome with SSRIs/SNRIs and other serotonergic drugs; it can cause (harmless) blue/green urine, and is dangerous in G6PD deficiency (hemolysis).
Only USP/pharmaceutical-grade material is safe — industrial dye is contaminated. It is used off-label/as a research chemical, not a dietary supplement.
The score reflects real but small human cognitive data and intriguing mitochondrial mechanisms against a narrow safe-dose window, serious drug interactions, and no human longevity evidence.
At low doses methylene blue cycles between oxidized and reduced forms in mitochondria, shuttling electrons to cytochrome c / oxygen and supporting ATP production.
Low doses are antioxidant and pro-bioenergetic; higher doses flip to pro-oxidant and harmful — a biphasic dose-response that defines the narrow safe window.
Methylene blue is a potent MAO inhibitor — relevant to mood/cognition but the basis of the serotonin-syndrome interaction risk.
How Methylene Blue works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated longevity dose. Nootropic use is LOW-dose (research used roughly 0.5–4 mg/kg in studies; biohacker oral use is often ~10–25 mg), USP-grade only. Higher doses become pro-oxidant and risk toxicity. Off-label/research use, not an approved regimen.
Can be taken without food
| Form | Type |
|---|---|
| 💊USP/pharmaceutical-grade low-dose oral | Recommended |
Industrial or aquarium-grade methylene blue is contaminated and unsafe — only USP grade should ever be ingested.
Minimum: 1 weeks
Optimal: 8 weeks
Cycling: Not required
Note: Low oral doses; never combine with serotonergic medications. USP grade only.
Dose-response data unavailable. The current published research for Methylene Blue does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Small randomized human studies show low-dose methylene blue can modestly improve memory-task performance and brain oxygen metabolism.
Supports cellular oxygen consumption and ATP production at low doses via electron-carrier activity.
Reduced oxidative stress and aging markers in skin-fibroblast models — cosmetic interest, not human-outcome proven.
As an MAO inhibitor it can cause serotonin syndrome with serotonergic drugs; higher doses are pro-oxidant; dangerous in G6PD deficiency.
Avoid — serious serotonin-syndrome risk.
Avoid — hemolysis risk.
Avoid — not established as safe.
Methylene blue is a potent MAO inhibitor — combining can cause life-threatening serotonin syndrome. A widely documented, serious interaction.
Can precipitate hemolysis in G6PD-deficient individuals.
Tip: Harmless and expected; dilute to reduce staining.
Tip: More likely at higher doses; keep doses low.
Tip: Do not combine with SSRIs/SNRIs/MAOIs — potentially life-threatening.
Tip: Avoid in G6PD deficiency.
Timing is flexible for Methylene Blue — consistent daily use matters more than the time of day. Low oral doses for cognition; stays in the low (antioxidant) part of the hormetic curve.
Methylene Blue should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are blue/green urine and oral staining, nausea / headache, serotonin syndrome (with serotonergic drugs). Use caution if any of these apply to you: Use with SSRIs/SNRIs/MAOIs or other serotonergic drugs (serotonin syndrome); G6PD deficiency (hemolysis); Pregnancy / breastfeeding.
A dietary flavonoid with anti-inflammatory effects in the lab. The honest verdict: the only direct human RCTs test PEA-luteolin combinations for post-COVID smell loss — isolated luteolin's anti-inflammatory, allergy, and brain claims rest on mechanism and reviews, not human trials, and its bioavailability is low.